# Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

> clinical trial · VERIFIED · 2026-06-30

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Progressive Multiple Sclerosis

- Company: Novartis Pharmaceuticals
- Sector: pharma
- Primary source: https://clinicaltrials.gov/study/NCT06675864

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.